Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Catholic University of the Sacred Heart
Sponsor:
Information provided by (Responsible Party):
Simona Di Giambenedetto, Catholic University of the Sacred Heart
ClinicalTrials.gov Identifier:
NCT01367210
First received: June 3, 2011
Last updated: July 30, 2014
Last verified: July 2014

June 3, 2011
July 30, 2014
June 2011
May 2015   (final data collection date for primary outcome measure)
proportion of patients with virological failure (two consecutive measures of HIV-RNA higher than 50 copies/mL or a single measure higher than 1000 copies/mL) within 48 weeks at per protocol analysis, with switch=failure [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01367210 on ClinicalTrials.gov Archive Site
  • proportion of patients with virological failure (two consecutive measures of HIV-RNA higher than 50 copies/mL or a single measure higher than 1000 copies/mL) within 96 weeks at intention-to treat analysis with missing value=Failure [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Time to virological failure at survival analysis [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients with at failure X4 tropism viral tropism (RNA or DNA genotyping) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Evolution of CD4 cell- cluster of differentiation 4 cell count during the 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Evolution of adherence and quality of life after 24, 48 and 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • Evolution of maraviroc, darunavir, ritonavir plasma concentrations during the 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Evolution of metabolic parameters at 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • Change of the results of neurocognitive tests at 48 and 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • Modification of bone density and subcutaneous fat at 48 and 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • Modification of Intima-Media Thickness and Flow Mediated Dilation at 48 and 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • Economic impact of Darunavir/ritonavir+ Maraviroc versus Highly Active Antiretroviral Therapy [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • proportion of patients with virological failure (two consecutive measures of HIV-RNA higher than 50 copies/mL or a single measure higher than 1000 copies/mL) within 96 weeks at intention-to treat analysis with missing value=Failure [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Time to virological failure at survival analysis [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients with at failure X4 tropism viral tropism (RNA or DNA genotyping) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Evolution of CD4 cell count during the 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Evolution of adherence and quality of life after 24, 48 and 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • Evolution of maraviroc plasma concentrations during the 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Evolution of metabolic parameters at 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • Change of the results of neurocognitive tests at 48 and 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • Modification of bone density and subcutaneous fat at 48 and 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • Modification of IMT and FMD at 48 and 96 weeks [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • Economic impact of DRV/r+ MVC versus CAT [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)
Switch to Darunavir/r + Maraviroc QD in Patients With R5 Tropism by Viral DNA Genotyping With Suppressed Viremia (GUSTA): a Multicenter, Open-label, Randomized Controlled Trial

Objectives of the study:

  1. To verify the safety and the efficacy of the study treatment, defined as the persistent control of the virus' replication at 48 weeks after the simplification to maraviroc + darunavir with ritonavir in patients with R5 tropism by viral DNA genotyping.
  2. To collect relevant information about the safety, the immunologic and the economic impact of this strategy.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infection
  • Drug: Maraviroc, Darunavir/r
    Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
  • Drug: current antiretroviral therapy with 3 drugs
    To continue the assumption of previous HAART
  • Experimental: MARAVIROC, DARUNAVIR/r
    Treatment simplification from a "standard" combined antiretroviral therapy including 3 drugs to Maraviroc plus Darunavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy
    Intervention: Drug: Maraviroc, Darunavir/r
  • Sham Comparator: current ART with 3 drugs
    Patients on HAART with three drugs and HIV RNA below 50 copies/mL
    Intervention: Drug: current antiretroviral therapy with 3 drugs
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
330
May 2016
May 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients treated with the same regimen including 3 HAART from at least 4 months
  • Aged 18 years or older
  • Who gave informed consent to the participation to the study
  • With at least two viral load < 50 copies/mL in two consecutive determinations at least 6 months apart (tolerance of two weeks)
  • With CD4 cell count > 200 cells/μL and absence of any opportunistic infection or AIDS-related disease for at least one year prior to the screening.
  • With R5 tropism by viral DNA genotyping (geno2pheno "clonal")
  • With CD4 cell count nadir>50 cell/mmc or 100 cell/mmc if previous enfuvirtide or integrase inhibitors use

Exclusion Criteria:

  • With at least one major or two minor mutation conferring resistance to darunavir reported in the update list of International AIDS Society - USA , in previous resistance test
  • Previous D/M or X4 viral tropism
  • Previous major clinical toxicities (grade >=3) to the proposed drugs of the study
  • Pregnancy or breast feeding, desire of pregnancy in the short term
  • Past exposure to Chemokine Receptor 5 antagonist
  • HBsAg serostatus
  • Liver cirrhosis of class C (Child-Pugh)
  • Sulpha drug hypersensitivity
  • The presence of major non AIDS-defining diseases that, in the opinion of the investigator, may compromise the retention of the patient in the study for the necessary follow-up period.
  • Estimated glomerular filtration < 30 ml/min (cockroft-Gaut; MDRD formula if black-African or african-american) at screening visit
  • Hypertransaminasemia of grade IV (more than 10 times the upper normal limit) at screening visit
Both
18 Years and older
No
Contact: Andrea De Luca, Prof 00390630154945 andrea.deluca@rm.unicatt.it
Contact: Manuela Colafigli, MD 00390630155366 manuela76@inwind.it
Italy
 
NCT01367210
2010-023316-13
No
Simona Di Giambenedetto, Catholic University of the Sacred Heart
Catholic University of the Sacred Heart
Not Provided
Principal Investigator: Andrea De Luca, Prof Catholic University of the Sacred Heart
Catholic University of the Sacred Heart
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP